01 December 2021 | News
The company ultimately aims to develop its own vaccine products to combat potential future pandemics
image credit- businesswire
Prestige BioPharma (PBP), a Singapore-based biopharmaceutical with operations in USA and South Korea, has announced the grand opening of its global-scale Vaccine Centre in Osong, South Korea. The opening ceremony was held on December 01, 2021.
PBP commenced construction of its Vaccine Centre April this year and completed the global-scale manufacturing facility with a total area of 10,342.88 sq mt and a total capacity of 104,000 litres (52 units of 2,000 liter bioreactors) in only eight months by employing Prestige Biologics’ proprietary engineering technology, ALITA Smart BioFactory.
PBP is currently focusing on two COVID-19 vaccine projects to produce Sputink V and Sputink Light vaccines. The new centre is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.
The centre will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID-19 vaccines.